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Human steroid 21-hydroxylase (ZI-OH) expressed in an in vitro translation system was found to react spezii?cally with adrenal autoantibodies from 
patients with Addison’s disease. The epitopes on Zl-OH which reacted with autoantibodies were studied by incorporating a series of terminal and 
internal deletions into the 21-OH gene and analysing the expressed proteins by Western blotting N-Terminal deletions up to amino acid 280 had 
no effect on autoantibody binding whereas a series of C-terminal deletions and truncations (amino acids 281-494) showed marked effects. Our 
results indicate that a central segment (281-379) and a C-terminal segment (38M94) of 21-OA interact to form at least one major autoantibody 
binding site. 
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Recent studies have shown that steroid 21-bydrox- 
ylase (21-OH) is a major autoantigen in adult onset 
autoimmune Addison’s disease [l-3]. In order to under- 
stand the molecular basis of adrenal autoimmunity it is 
necessary to character& the autoantigenic epitopes on 
21-OH. Consequently, we have prepared a series of de- 
letions and truncations in the 21-OH gene, expressed the 
corresponding proteins and analysed their interactions 
with adrenal autoantibodies. 
2. CABALS AND METHODS 
2.1, Patients 
Sera were obtained from 11 patients with adult onset autoimmune 
Addison’s disease. All the sera contained autoantibodies to 2l-OH 
and were part of the Addison sera panel we have described previously 
[l]. Sera were also obtained from 3 Hashimoto’s disease patients, 3 
Graves’ disease patients, 3 rheumatoid arthritis patients and 9 healthy 
laboratory staff. 
2.2. Plasmid co~t~tio~ 
Various in-frame deletions and truncations of the 21-OH gene were 
carried out by cutting at differen restriction enzyme sites. The modi- 
fied genes were cloned into pYES express&u vectors and expressed in 
vitro as described below. 
The full-length 2l-OH gene was cloned into pYES2 as described 
previously [l] and the resulting construct defined as p2l-OH1 (Table 
I). The restriction enzyme sites used to prepare the various U-OH gene 
modifications are showu in Table I and Fig. 1. In the case of construct 
p2l-OHl1, an extension coding for 12 homologous amino acids was 
added at the S&I site (Table I). 
Truncated and deleted versions of the 21-OH gene were cloned into 
pYES3, a derivative of the yeast expression vector pYES2 (Invitro- 
*Corresponding author. Fax: (44) (222) 761175. 
gen). The vector pYES3 was constructed from pYES2 by ctoning a 
linker into the EcoBI and &&I sites of the multiple CIoniug site of 
pYES2. The unique iinker, prepared by annealing two ohgouucieo- 
tides {5‘-AATTCCCTGAGGCCACGTGACTGACTGAGCATG-3’ 
and 5’-CTCAGTCAGTCACGTGGCCTCAGGG-3’) was designed 
to include SuuI and k&PI restriction sites for cloning and a series of 
TGA stop codons which ensured translation termination of all the 
truncated 21-OH genes. 
2.3. In vitro transcriptionltransiation 
The various Zl-OH gene constructs (Table I, Fig. 1) were trau- 
scribed and translated in a rabbit reticulocyte lysate system using a 
Promega TnT ~~~ptio~~slation kit. Synthesis of proteins 
coded for by the various constructs was assessed by in&ding 
[3’S$uethionine in the tr~~ptio~t~s~~on reactions. The lab&led 
proteins were then run on acrylamide gels (9%) in SDS and aualysed 
by autoradiography. 
Reactions without added [3*S&r&hionine were analysed on SDS- 
PAGE followed by Western blotting using 2l-OH autoantibodies. In 
addition, Western blotting was carried out with a rabbit antibody to 
21-OH (1,3,4) kindly provided by Dr. Bon-chu Chung. 
2.4. Expression in yetut 
Expression of full-length 21-hydroxyiase in Saccharomyces cerevis- 
iae and preparation of yeast extracts was as described previously [l]. 
3. REsutTS 
When different constructs were expressed in the in 
vitro tr~~~ptio~~~ation system in the presence of 
[35S]methionine, iabelled recombinant proteins of the 
expected molecular weights (32 kDa-55 kDa) were de- 
tected in every case (Fig. 2a, Table I). In addition, West- 
ern blot analysis indicated that all but 2 of the recombi- 
nant proteins (from constructs p21-OH4 and p21-0H5) 
reacted with rabbit antibodies to 21-OH (Table I, 
Fig. 2b). 
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Table I 
Reactivity of full-length and modified human steroid 21-OH with Addison’s sera and rabbit antibody 
Construct 
p21-OHl 
p21-OH13 
p&OH1 1 
p2l-OH2 
p21-OH3 
p21-OH4 
p21-OHS 
p21-OH6 
~21.OH10 
~21.OH7 
p21-GH12 
Enzyme sites 
used 
None 
~~~EeoRI 
SruI (linker)* 
&#I 
BsrXI 
SauI 
BbrPI 
PvUII/PvaII 
PvaIUBbrPI 
EcoRKSauI 
SauUBstXI 
Modified 21-OH 
Amino acids Region of 
deleted deletion 
None None 
U-162 N-te~nal 
460-494 C-terminal 
448-494 C-terminal 
418-494 C-terminal 
381-494 C-terminal 
282-494 C-terminal 
142-240 Internal 
142-280 Internal 
165-379 Internal 
382-414 Internal 
Mol. wt** &Da) 
of expressed 
protein 
55 
42 
48 
48 
46 
43 
32 
45 
39 
34 
48 
Reaction with 21-OH antibody 
Addison sera Rabbit 
(proportion Antibody 
reacting) 
(11111) + 
(11111) + 
(5111) + 
(4111) + 
(4/l 1) + 
(1111) 
(O/3) 
(515) + 
(11111) + 
(O/l 1) + 
(7/l 1) + 
*Oligonucleotide linker coding for 12 amino acids of 2l-OH additional to the truncation created at the Stul site. 
**Mel wt of 21-OH was determined by SDS-PAGE of in vitro translation reactions. . . 
Analysis of autoantibody binding to f~l-lend and 
modified recombinant 21-OH is summarised in Table I. 
Autoantibodies in all 11 Addison sera studied reacted 
with full-length 21-OH expressed in vitro (construct 
p21-OHI, Table I and Fig. 2c, lane 6). Furthermore, an 
N-terminal deletion of amino acids 15-162 (construct 
p21-0H13) had no effect on autoantibody binding 
(Table I). In addition, 2 deletions of amino acids (142- 
240 and 142-280; constructs p21-OH6 and p21-OHlO) 
overlapping with this region did not influence autoanti- 
body binding (Table I and Fig. 2c, lane 5). 
Initial experiments with a C terminai t~cation (con- 
struct p21-OH5) indicated that 313 sera strongly positive 
for 21-OH autoantibodies were unable to recognise 21- 
OH with amino acids 282-494 deleted pig. 2c, lane 4 
and Table I). 
These studies were then extended to include all 11 
sera and a series of C-terminal truncations and dele- 
tions. The results were as follows: 
(a) None of the 11 sera reacted with 21-OH with amino 
acids 165-379 deleted (construct p21-0H7). 
(b) Only 1 out of 11 sera reacted with the protein trun- 
cated at amino acid 381 (construct p21-0H4). 
(c) 4 out of 11 sera reacted with 21-OH truncated at 
amino acids 418 or 448 (constructs ~21 -OH3 and p21- 
OH2, respectively). 
(d) 5 out of 11 sera reacted with the protein truncated 
at amino acid 460 (instruct p21-OHli). These 5 sera 
included all the 4 sera which reacted with 21-OH trun- 
cated at amino acid 448. 
(e) 7 out of I1 sera reacted with Z-OH with amino 
acids 382-414 deleted (construct p21-0H12). 
BunHI 
5’ ’ 
Nar 1 
15 
N -r: 
Pwll PWII 
1 EmilI 1 EbrPI 
141163 240 239 
BStXI 
SW1 1 SmI 
379 416 447 
13’ 1502bp 
*c 494AA 
N c 
k+----- 15-230 -c( 
t 
+-350.4944 
I---ma-97vr( 
Fiegidn noI involved 
in auhnllbody binding 
Fig. 1. The restriction enzyme map and amino acid sequence of human 
steroid 21-GIi are shown in schematic form. fJ, Signal peptide (amino 
acids 1-14 are part of the ST&? leader peptide [l]). Regions involved 
in autoantibody binding IPB, segment 1; B, segment 2; q , region not 
involved in auto~ti~y binding; 8, presumptive substrate-biding 
Fig. 2. Analysis of full-length and modified human steroid 21-OH 
produced using an in vitro translation system. (a) [3SS]Methionine- 
labelled reactions analysed by SDS-PAGE and autoradiography. 
pYES3 (vector only) (lane l), p21-OH2 (amino acids 448-494 deleted) 
(lane 2), p21-OH5 (amino acids 282494 deleted) (lane 3), p2l-OH6 
(amino acids 142-240 deleted) (lane 4). p21-OH4 (amino acids 381- 
494 deleted) (lane 5), p21-OH1 (f~-lend) (lane 9. (b) Reactions 
analysed by SDS-PAGE and Western blot with rabbit anti-hnman 
2l-OH antibody. pYES3 (vector only) (lane I), p21-OH2 (lane 2), 
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
6), p21-OH1 expressed in yeast (lane 7). The ECL system (Amersham 
International) was used to detect antibody reactivity. (c) Reactions 
analyscd by SDS-PAGE and Western blot (ECL system) with pooled 
serum from 4 Addison’s patients. Results obtained when Western 
blotting was performed with 11 individual Addison’s sera are sum- 
marised in Table I. pYES3 (vector only) (lane l), p21-OH2 (lane 2), 
p21-OH4(lane 3), p2l-OH5(lane4),p21-OH6(lane S), p21-OH1 (lane 
6) ~21.OH1 expressed in yeast (lane 7). No specitlc reactions were 
observed with normal rabbit serum, normal human sera or sera from 
3 Hashiioto’s, 3 Graves’ or 3 rhe~atoid arthritis patients (data not 
site; V, cysteine at position 428 involved in haem-boding. shown). 
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97k 
66k 
45k 
29k 
1 234567 
b 205k -+ 
116k * 
97k * 
66k * 
1 234567 
205k 
116k 
97k 
66k 
45k 
29k 
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4. DISCUSSION 
Our results show that 21 -OH expressed in the in vitro 
transcription/translation system binds 21-OH autoanti- 
bodies. 
All sera tested reacted with the protein modified by 
N-terminal deletions: between amino acids 15-162, 
142-240 and 142-280 (Table I and Fig. 2c, lane 5). This 
indicates that amino acids 15-280 are not important for 
autoantibody binding to 21-OH. 
None of the sera tested reacted with 21-OH modified 
by deletion of amino acids 165-379 (Table I). As this 
deletion overlaps (from amino acids 165-280) with the 
deletions which are not required for autoantibody bind- 
ing (see above), it could be concluded that the segment 
between amino acids 281 and 379 (segment 1, Fig. 1) is 
important for autoantibody binding. 
However, only one serum reacted with the 21-OH 
protein truncated at amino acid 380. In the case of the 
other sera, varying stretches of the C-terminal portion 
(amino acids 380-494; segment 2, Fig. 1) were also re- 
quired for autoantibody binding (Table I). This suggests 
that amino acids in segment 2 are also important for 
autoantibody binding. As none of the sera reacted with 
segment 2 in the absence of segment 1 (see above) and 
all but one of the sera needed segment 2 for binding, it 
seems likely that segment 2 co-operates with segment 1 
in forming at least one major autoantibody binding site. 
As 2 distinct regions of 21-OH co-operate to form this 
site, it would appear to be conformational in nature. In 
the case of the one serum which reacted with segment 
1 without the need for a contribution from segment 2, 
the autoantibodies may be directed to a linear epitope 
in segment 1 or a conformational epitope in segment 1 
which does not depend on segment 2. 
One of the recombinant 21-OH proteins which re- 
acted with some of the autoantibodies did not react with 
rabbit 21-OH antiserum. Furthermore, the rabbit anti- 
serum bound to one of the modified proteins which was 
not recognised by autoantibodies (Table I) indicating 
that the antiserum contained antibodies to different ep- 
itopes than those recognised by the autoantibodies. 
The nature of autoantibody binding sites tends to be 
conformational; for example, in the case of the thyroid 
autoantigens thyroglobulin and thyroid peroxidase [5- 
71. Although they appear conformational, the major 
autoantibody binding sites on 21-OH are sufficiently 
robust to reform after electrophoresis in SDS under 
reducing conditions. This probably reflects the special 
renaturing treatment of the blotted proteins which we 
used prior to interaction with autoantibody [8]. As the 
adrenal autoantibodies react with reduced 21-OH, the 
formation of the major autoantibody binding sites does 
not appear to be dependent on disulphide bridge integ- 
rity. 
It is of interest that the 2 segments of 21-OH shown 
to be important for autoantibody binding are also im- 
portant for 21-OH enzyme activity. In particular, the 
region 342-358 within segment 1 contains the substrate- 
binding site [9] and the cysteine at 428 (within segment 
2) is a part of the haem-binding site (Fig. 1) [lo]. 
Our results with 21-OH can be compared with a very 
recent report on autoantigenic epitopes on glutamic 
acid decarboxylase (GAD) a major autoantigen in dia- 
betes [ll]. In the case of GAD a central region and a 
C-terminal region of the molecule are involved in form- 
ing 2 major conformational epitopes. Interestingly, the 
C-terminal region of GAD is also important for enzyme 
activity [ 111. 
Overall our studies indicate that while the N-terminal 
half of 21-OH is not involved in autoantibody binding; 
a central and a C-terminal region interact to form at 
least one major conformational autoantibody binding 
site. 
Acknowledgements: We are grateful to Dr. Bon-chu Chung for provid- 
ing antibodies to recombinant human 21-hydroxylase. This work was 
supported by RSR Ltd., Cardiff. Drs. Bamnann-Antczak and Asawa 
were in receipt of RSR Fellowships. 
REFERENCES 
[l] Bednarek, J., Furmaniak, J., Wedlock, N., Kiso, Y., Baumann- 
Antcxak, A., Fowler, S., Krishnan, H., Craft, J.A. and Rees 
Smith, B. (1992) FEBS L&t. 309, 51-55. 
[2] Winqvist, O., Karlsson, EA. and Kampe, 0. (1992) Lancet 339, 
1559-1562. 
[3] Baumann-Antczak, A., Wedlock, N., Bednarek, J., Kiso, Y., 
Krishnan, H., Fowler, S., Rees Smith, B. and Furmaniak, J. 
(1992) Lancet 340,429430. 
[4] Hu, M.-C. and Chung, B.-c. (1990) Mol. Endocrinol. 4,893-898. 
[5] Finke, R., Seto, P. and Rapoport, B. (1990) J. Clin. Endocrinol. 
Metab. 71, 53-59. 
[6] Kiso, Y., Furmaniak, J., Morteo, C. and Rees Smith, B. (1992) 
Autoimmunity 12, 259-269. 
[7] Laver, W.G., Air, G.M., Webster, R.G. and Smith-Gill, S.J. 
(1990) Cell 61, 553556. 
[8] Birk, H.-W. and Koepsell, H. (1987) Anal. Biochem. 164, 12-22. 
[9] Chiou, S.-H., Hu, M.-C. and Chung, B.-c. (1990) J. Biol. Chem. 
265, 3549-3552. 
[lo] Yoshioka, H., Morohashi, K., Sogawa, K., Yamane, M., Komi- 
nami, S., Takemori, S., Okado, Y., Omura, T. and Fujii-Kuri- 
yama, Y. (1986) J. Biol. Chem. 261, 41064109. 
[ll] Richter, W., Shi, Y. and Baekkeskov, S. (1993) Proc. Nat]. Acad. 
Sci. USA 90,2832-2836. 
126 
